Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) – Analysts at Cantor Fitzgerald issued their FY2016 earnings estimates for shares of Paratek Pharmaceuticals in a research report issued on Tuesday. Cantor Fitzgerald analyst C. Russo anticipates that the brokerage will post earnings per share of ($5.73) for the year. Cantor Fitzgerald has a “Buy” rating and a $28.00 price target on the stock. Cantor Fitzgerald also issued estimates for Paratek Pharmaceuticals’ FY2017 earnings at ($4.37) EPS.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its quarterly earnings results on Wednesday, November 2nd. The specialty pharmaceutical company reported ($1.04) EPS for the quarter, topping analysts’ consensus estimates of ($1.38) by $0.34.

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The legal version of this story can be read at http://www.watchlistnews.com/research-analysts-offer-predictions-for-paratek-pharmaceuticals-inc-s-fy2016-earnings-prtk/1061059.html.

Other equities analysts have also issued research reports about the stock. Robert W. Baird set a $40.00 target price on shares of Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Sunday, November 20th. Leerink Swann reiterated a “buy” rating and set a $23.00 price objective on shares of Paratek Pharmaceuticals in a report on Thursday, November 3rd. BTIG Research initiated coverage on shares of Paratek Pharmaceuticals in a report on Thursday, December 22nd. They set a “buy” rating and a $47.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, January 4th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. Paratek Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $33.86.

Paratek Pharmaceuticals (NASDAQ:PRTK) opened at 15.45 on Friday. The company’s market cap is $349.59 million. Paratek Pharmaceuticals has a 12-month low of $9.80 and a 12-month high of $18.92. The company’s 50-day moving average price is $13.96 and its 200-day moving average price is $13.20.

Several large investors have recently bought and sold shares of the company. LPL Financial LLC raised its stake in Paratek Pharmaceuticals by 11.3% in the third quarter. LPL Financial LLC now owns 29,450 shares of the specialty pharmaceutical company’s stock worth $403,000 after buying an additional 3,000 shares in the last quarter. Credit Suisse AG raised its stake in Paratek Pharmaceuticals by 53.1% in the third quarter. Credit Suisse AG now owns 16,284 shares of the specialty pharmaceutical company’s stock worth $212,000 after buying an additional 5,649 shares in the last quarter. Candriam Luxembourg S.C.A. raised its stake in Paratek Pharmaceuticals by 50.0% in the third quarter. Candriam Luxembourg S.C.A. now owns 60,000 shares of the specialty pharmaceutical company’s stock worth $781,000 after buying an additional 20,000 shares in the last quarter. Croft Leominster Inc. acquired a new stake in Paratek Pharmaceuticals during the third quarter worth $188,000. Finally, Highbridge Capital Management LLC acquired a new stake in Paratek Pharmaceuticals during the third quarter worth $501,000. Institutional investors own 75.62% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was copied illegally and republished in violation of US & international copyright laws. The legal version of this story can be read at http://www.watchlistnews.com/research-analysts-offer-predictions-for-paratek-pharmaceuticals-inc-s-fy2016-earnings-prtk/1061059.html.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

5 Day Chart for NASDAQ:PRTK

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.